Literature DB >> 11929398

One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies.

W M Wong1, B C Y Wong, H Lu, Q Gu, Y Yin, W H Wang, F M Y Fung, K C Lai, H H X Xia, S D Xiao, S K Lam.   

Abstract

AIM: To test the efficacy of omeprazole, furazolidone and amoxicillin triple therapy for the treatment of Helicobacter pylori infection after failure of standard first-line therapy recommended by the Asia-Pacific Consensus on the management of H. pylori infection.
METHODS: Patients with failed H. pylori eradication received omeprazole, 20 mg, furazolidone, 100 mg, and amoxicillin, 1 g, all twice daily for 1 week. Endoscopy (CLO test, histology and culture) was performed before treatment. Post-treatment H. pylori status was determined by 13C-urea breath test 6 weeks later.
RESULTS: Fifty patients were recruited. Resistance to metronidazole, clarithromycin and both drugs was in the range of 50-64%, 60-75% and 40-50%, respectively, after failure of first-line therapy. Amoxicillin resistance was not found. The intention-to-treat and per protocol H. pylori eradication rates were 52% and 53%, respectively. Patients with double resistance to metronidazole and clarithromycin showed the lowest eradication rate (38%), which was significantly lower than that of patients with sensitive strains (88%). Side-effects were minimal and compliance was excellent (98%).
CONCLUSIONS: One-week omeprazole, furazolidone and amoxicillin rescue therapy achieved a high eradication rate in strains sensitive to metronidazole and clarithromycin. This is a cheap and safe rescue regimen when guided by pre-treatment sensitivity testing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929398     DOI: 10.1046/j.1365-2036.2002.01223.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Update on Therapeutic Options for Helicobacter pylori-related Diseases.

Authors:  Francis Mégraud
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

2.  Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.

Authors:  Hong Cheng; Fu-Lian Hu
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

Review 3.  Basis for the management of drug-resistant Helicobacter pylori infection.

Authors:  Francis Mégraud
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

Review 5.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

6.  Laboratory diagnosis and susceptibility profile of Helicobacter pylori infection in the Philippines.

Authors:  Raul V Destura; Eternity D Labio; Leah J Barrett; Cirle S Alcantara; Venancio I Gloria; Ma Lourdes O Daez; Richard L Guerrant
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-11-16       Impact factor: 3.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.